Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Poloxamer 407 walked onto the scientific stage in the 1950s, crafted by BASF chemists searching for new surfactants with unique solubility traits. Back then, researchers wanted to tackle the trouble of delivering stubborn drugs into the human body more smoothly. Years of exploration carved out an entire class known as poloxamers, but 407 stood out for its curious behavior around temperature and water. In practice, those original breakthroughs didn’t just sit in academic journals; they showed up in labs, hospitals, and factories, changing how modern pharmaceuticals looked at solubility and bioavailability. Now, it sits inside dozens of well-known products, from prescription medicines to those over-the-counter ointments people reach for on tough days.
Poloxamer 407 isn’t a household name, but its role shapes industries. Go through the ingredient lists of injectable medications, topical gels, or even some processed foods, and there’s a good chance this white, waxy solid plays a part. Its alternate names—Pluronic F127, Synperonic PE/F127—show up globally. Manufacturers, especially in the pharmaceutical sector, rely on it to make solutions, gels, and emulsions. Heading across markets, you’ll find its regulated forms, bearing strict pharmacopoeial grades like BP, EP, and USP, proving each batch meets promised standards and identity.
Poloxamer 407 stands out as a block copolymer, pieced together from polyethylene oxide and polypropylene oxide. Its molecular weight averages about 12,600 g/mol, which shapes its handling in the lab and in products. The polymer forms a pasty solid at room temperature, but stir it into water at the right concentrations and it becomes a liquid that transforms into a firm gel once warmed. This “thermoreversible” gelling allows creative drug delivery and brings doctors closer to targeted therapies. Its nonionic nature keeps interactions simple, limiting chemical reaction risks, while the distinct block structure lets it carry fat-soluble and water-soluble molecules side by side.
Look at a fresh shipment in a manufacturing plant: technical sheets follow each drum, stating purity (typically above 99%), residual solvent limits, and heavy metal content that nudges close to zero. Labeling laws, enforced by regulators like the FDA and EMA, require every package to announce grade, exact lot, country of origin, and relevant pharmacopoeial compliance (BP, EP, USP). Batch traceability lets both regulators and end-users chase down the smallest issues if something goes wrong. Storage guidelines warn about sunlight, humidity, and heat—excessive exposure can push the powder to cake or turn yellow, risking both product and patient safety.
Manufacturing Poloxamer 407 is a dance of polymer chemistry. It starts with the basic building block: propylene oxide, pushed into a reaction vessel under pressure. Once the right length forms, scientists slip in ethylene oxide for a second pass, building outer shells. Reaction times and temperatures need tight control—too hot or too long, and you end up with useless gunk or off-spec polymer. Next comes multi-step purification, with repeated washing and drying under low-oxygen, low-moisture conditions, leaving behind a powder or solid block. These steps get repeated at industrial scale, checked every few hours by process chemists run through gas and liquid chromatography.
Not many polymers keep their character across so many tweaks, but scientists still tinker. Reacting Poloxamer 407 with small molecules—say, fatty acids or amines—yields modified copolymers aimed at targeted drug delivery or improved emulsifying action. Some labs graft charged groups onto the backbone for better tissue targeting, or thread in other polymers for composite gels that can hold or release drugs on demand. Despite this flexibility, the core integrity rarely budges, so fundamentals in biocompatibility stay reliable even after adaptation.
Global pharmaceutical and chemical catalogs offer Poloxamer 407 under an array of names: Pluronic F127 in North America, Synperonic PE/F127 through European and Asian distributors, Kolliphor P 407 from BASF, and a handful of local trademarks that change by region and distributor. This variety often complicates procurement and regulatory documentation, especially when switching suppliers or submitting paperwork across borders. Each variant promises comparable performance, but careful buyers dig through spec sheets to confirm purity, molecular length, and compliance grade instead of trusting a name.
The safety profile of Poloxamer 407 builds confidence among healthcare professionals. Decades of toxicity data under BP/EP/USP standards confirm low irritation, non-sensitization, and absence of mutagenicity in typical uses. Manufacturing settings implement dust controls to protect workers from nuisance exposure—though not directly harmful, airborne particles clog filters and line lungs. Handling procedures usually require gloves, masks, and scrupulous labeling to prevent accidental swaps, thanks to its near-identical siblings like 188 or 338, which serve very different uses. Storage demands cool, dry places in sealed containers, with expiry monitoring to guard against polymer breakdown.
Pharmacies and hospitals benefit most from Poloxamer 407. Injectable suspensions, eye drops, and topical ointments depend on its gentle, reliable carrier abilities. In these, it dissolves otherwise tricky-to-handle ingredients, suspending them in a stable, easy-to-dose gel or solution. More recently, I’ve seen wound care and tissue engineering specialists using it as a scaffolding because it lets cells grow into healing patterns, while its biocompatibility keeps immune reactions at bay. Cosmetics and personal care companies chase its mild, smooth sensation for lotions and cleansers. Food technologists tap it in niche applications for stabilizing flavor or fat dispersions, though regulations clamp down hard on what’s allowed. Each field pushes at the boundaries, extending uses as new properties come to light.
Applied science never stands still, and Poloxamer 407 draws ongoing research across continents. Universities explore combinations with novel therapeutic agents, seeking room-temperature liquids that solidify into drug-release gels inside the body. These systems hope to improve cancer therapy, pain control, and long-acting antibiotics. Some researchers chase its potential in gene delivery, binding DNA or RNA for direct transport through cell walls. Other teams look to blend it with smart polymers, programming custom temperature or pH sensitivity to fine-tune how active ingredients reach their targets. Lab successes prompt cautious optimism but demand rigorous human trials before big promises make headlines.
Animal studies and human trials assign Poloxamer 407 high marks for safety in approved doses. Absorption through the skin or gut clears through the kidneys without lingering in tissues, avoiding buildup or long-term health worries—unlike some older excipients that quietly built up, causing metabolism issues. Toxicologists always keep a close watch. High doses, thousands of times higher than pharmaceutical exposures, can still disrupt liver enzymes or kidney function in rodent models, though no medical formulations come close to these levels. Post-market surveillance stays vigilant, scanning for rare allergic or toxic responses. This systematic approach anchors its trust in clinical settings.
Poloxamer 407 will show up in many more applications than today’s market hints. As drug delivery moves toward more personalized, targeted solutions, the flexibility and track record of this polymer invite fresh strategies and tailored therapies. Advances in regenerative medicine and 3D-printed tissue scaffolds push for gels that mirror the body’s subtle temperature changes—an area where Poloxamer 407 fits naturally. Environmental science may even find uses in water treatment and pollution cleanups, thanks to its unique solubilizing properties. Development teams should keep exploring its modifications and blends but will need to keep regulatory authorities close, as new uses and exposure patterns prompt renewed scrutiny. In my years following excipient trends, few have threaded the needle between versatility, safety, and continuous research as neatly as this one. New discoveries will depend on careful collaboration between chemists, clinicians, and watchdog agencies.
I’ve seen plenty of ingredients come and go in the world of pharmaceuticals, but Poloxamer 407 holds a special spot for good reason. You find it under the names Pluronic F127, and sometimes, just “poloxamer.” The letters BP, EP, and USP show that it matches standards for British, European, and US Pharmacopeias—which reassures everyone from pharmacists to patients that the ingredient meets the highest purity benchmarks.
I spent time working in compounding pharmacies and the thing about Poloxamer 407 is simple—it makes drugs easier to deliver and improves patient experience. It’s far from a secret weapon anymore, but its uses speak to why it remains popular.
In topical creams, Poloxamer 407 provides structure and a pleasing feel. It works as a gelling agent, thickening formulations so they stay where you put them. For example, a hospital-grade wound gel will often feature it because once it hits skin temperature, it goes from a liquid to a soft gel. That’s not just a parlor trick—it lets nurses and doctors apply medicine gently without it running off and making a mess.
Injectables benefit too—Poloxamer 407 helps create slow-release drug formulations. Take a diabetes medicine that needs steady release under the skin; Poloxamer 407 forms a depot, keeping the medicine in place so it releases over hours or days. This matters for anyone sick of constant injections.
Seen many doctors appreciate its use in eye medicines. Eye drops tend to wash out quickly, but by adding Poloxamer 407, the drop clings longer, letting more of the medicine do its job. Patients do notice the difference, and so do results.
The food and cosmetics industries use pharma-grade Poloxamer 407, too. I’ve observed it make tough-to-mix solutions blend smoothly—think toothpaste that feels even on the teeth, or a mouthwash that doesn’t separate in the bottle. Its safety profile, tested repeatedly in human and animal studies, gives manufacturers confidence when including it in products intended for daily use.
Not every version of Poloxamer 407 is equal. BP, EP, and USP grades stand up to tight quality control, reducing risks from contaminants or inconsistent performance, especially for injections or medicines for the eyes. Contaminated or low-grade ingredients can cause irritation or worse. The industry learned hard lessons from past mistakes with untested excipients; now, manufacturers favor only those materials tested by reliable standards. It’s not just about following rules—it’s about protecting the people who count on these medicines.
Regulators don’t just scrutinize active ingredients; they keep a close eye on excipients like Poloxamer 407, too. Pharmacists and manufacturers know the importance of sourcing only certified grades. From my time helping design topical gels and sterile products, I’ve seen how a subpar ingredients list can halt an entire project. Training, documentation, and audits must back every step from supplier to finished product.
As more new drug types emerge, Poloxamer 407 will keep finding new uses. But real progress depends on each lab, pharmacy, and manufacturer taking responsibility for what goes into the final mix. Following the strict standards of BP, EP, and USP isn’t a legal hurdle—it's the baseline for building trust and ensuring that people receive the safest and most reliable care.
Most folks never spot Poloxamer 407 on a medicine label, but it’s there, moving quietly behind the scenes. This synthetic block copolymer brings a unique property to drug delivery: it shifts from liquid to gel in response to temperature. It can help creams glide across the skin or keep drugs stable in your bloodstream. Yet, for every “invisible” ingredient, safety is everything. I’ve seen how one overlooked additive can derail a therapy or shake a patient’s confidence.
Years working in a pharmacy and watching patients scan leaflets taught me people care about every part of their medication, active or otherwise. So the quiet questions about excipient safety never really stop. That includes Poloxamer 407, which pharmacopoeias like BP, EP, and USP recognize as pharmaceutical grade. Meeting all three standards tells you the polymer consistently clears high quality bars for identity, purity, and performance. That’s a must for any material landing in intravenous, topical, or oral medicines. These standards aren’t theoretical—they shape inspections, batch records, and recalls. Regulators do not shy away from pulling products for shortfalls, even with a substance as familiar as this one.
Preclinical studies give us the early clues. Researchers noticed some strange effects in animals given very high doses. Mice on hefty levels of Poloxamer 407 had increased cholesterol, which set off medical alarm bells in the late 1990s. Follow-up work, and design differences in studies, suggested these results came from doses far above what any patient would actually encounter. At realistic, regulated strengths, Poloxamer 407 passes scrutiny for toxicity, irritation, and allergic potential. You’ll see it in eye drops, wound gels, and vaccine delivery systems—places where a risky ingredient would stand out fast.
I’ve spoken with compounding pharmacists who say they trust Poloxamer 407 next to classic standards like polyethylene glycol. You’ll catch its name in clinical trials, too, trying to stabilize insulin or anchor cancer drugs with delicate structures. Adverse event reporting systems almost never call out this polymer as a culprit. That track record over decades says something, especially in a risk-wary industry.
Every ingredient in a medication takes a long, grueling path to approval. Manufacturers must prove their raw Poloxamer 407 is pure—no heavy metals, no residual solvents, no bacteria. Each batch comes with documentation. Pharmacies and hospitals store it away from heat and light because breakdown can cause real problems. Pharmacists routinely ask manufacturers for certificates of analysis that show all contaminants fall below safety limits. This isn’t optional. If the documentation doesn’t look right, that batch goes nowhere near a patient.
More watchdogs watch for new risks now than ever. Post-market surveillance from health authorities helps catch allergic reactions in rare populations. If someone does react, the event gets tracked and flagged. That kind of attention builds trust, but there’s no resting on past “safe” labels.
No ingredient, synthetic or natural, is free of risk or beyond improvement. The best path forward includes routine research, wider allergen testing, and full transparency with patients. I’d recommend doctors mention excipients like Poloxamer 407 to anyone with a history of allergies. People feel safer when the whole formula is out in the open—and that honesty helps catch rare issues sooner.
Staying grounded, we count on both science and common sense: established safety, tough standards, and respect for individual needs. That’s the approach that keeps pharmaceutical innovation worthy of public trust.
Poloxamer 407 shows up in a surprising range of products, from drug delivery systems to gels in personal care. In pharmaceutical circles, quality can't take a back seat, so the British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP) each list strict expectations for this polymer.
Poloxamer 407 falls into the block copolymer category, combining polyethylene oxide and polypropylene oxide. Across the BP, EP, and USP, the average molecular weight lands around 10,000–15,000. The content of ethylene oxide should measure between 72% and 83%. On the flip side, propylene oxide sits between 17% and 28%. These percentages guarantee stable water solubility and gelation behavior—qualities crucial for both creams and drug carriers.
Every pharmacist and chemist knows that small impurities create big problems. The standards say Poloxamer 407 needs to look clear or nearly so—free from specks, colors, or odd smells. This isn’t about looks alone. A clear substance tells you no hidden chemicals are present that could spark allergic reactions in a cream or dangerously change the way a drug gets absorbed in the body.
Heavy metals get a hard cap, usually below 20 ppm. This rule matters because metals as trace contaminants risk patient health, especially in injectable medications. Loss on drying, another measured factor, shouldn’t crack 0.5%. Water affects both stability on pharmacy shelves and how a finished gel feels against skin.
Acidity and alkalinity land inside a pH window (5.0–7.0), hinting at chemical stability and protection for sensitive skin. Residue on ignition, meant to catch lingering inorganic particles, stays under 0.25%. Put simply, residues can mess with consistency and open the door to ingredient clashes.
Thinking back to days spent troubleshooting compounding issues, I remember batches ruined when small differences in polymer purity led to clumpy gels or rapid phase separation. Meeting pharmacopoeial standards isn’t just a rubber stamp—it’s a difference visible in the performance and appearance of the final product.
Tests using gel permeation chromatography confirm molecular weight. Gas chromatography checks for early-stage raw material leftovers, like ethylene oxide or propylene oxide. Infrared and NMR spectroscopy have their roles too, checking for both correct structure and hidden additives. The exact mix of tests might shift depending on country, but the fundamentals don’t budge.
Mistakes in meeting monograph specs can cost a manufacturer more than just regulatory grief. Bad batches cause consumer distrust. Regulatory authorities have cracked down harder on raw material testing since recalls involving contaminants over the past decade. Automated systems, digital batch tracking, and staff training can all improve batch conformity. Sometimes, though, it takes direct conversations between manufacturers and end users to clear up where mismatches are cropping up.
Every material in a product forms part of the healthcare promise. Sticking to these standards—meticulously documented by BP, EP, and USP—protects both innovation and consumer safety. Consistent, pure Poloxamer 407 means reliable medicine and personal care goods, no matter where someone lives.
Poloxamer 407 is often used in pharmaceuticals and personal care products. From my time working in a small contract lab, it’s clear that simple mistakes in how chemicals are stored can make the difference between high-quality results and a batch no one trusts. This isn’t just about ticking boxes for compliance. Poloxamer 407, based on its structure, can attract moisture and even degrade if not looked after. There’s money on the line, but more importantly, patient trust hangs in the balance.
Direct heat and sunlight chip away at reliability. Poloxamer 407 should be kept cool and dry—think storage below 25°C, away from sources of warmth and humidity. I’ve seen storerooms that skip A/C on weekends to save money, which ruins temperature-sensitive stock. It’s a risk that stacks up quickly, since the quality certification carries little weight if the product changes in storage. Humidity, especially above 50%, can clump the powder or lead to unexpected gel formation. A sealed container in a dedicated climate-controlled space helps prevent costly waste.
I always tell new staff to double-check containers before shelving anything. One faded label, one cracked lid, and data goes out the window. Pharmaceutical-grade Poloxamer 407 usually comes in tamper-evident pails or drums with airtight seals—keep it that way. Improperly closed packaging makes the material a magnet for ambient moisture, dust, and microorganisms. The best practice involves labeling each container clearly with the batch number, expiration date, and receiving date right on the side. This isn’t overkill; I’ve tracked down contamination to a single jar once left open for ‘just a minute’.
Lab coats, gloves, and masks sound like overkill, but every step without them raises the risk of contamination. I’ve seen operators grab a scoop without gloves, later discovering the transfer introduced unintended residues. Transfer tools, like scoops and funnels, need cleaning before and after every use with validated methods that remove both residue and possible microbial hitchhikers. Sticking to single-use containers or dedicated equipment for poloxamer lots can keep cross-contamination out of the picture.
Rotating stock using the ‘first in, first out’ method means you don’t end up with forgotten, expired batches at the back of a shelf. Keep detailed logs of temperature, humidity, and product movement. A digital tracking system with alerts for expiry helps sidestep a world of headaches. Audit trails make it easier to respond when a regulator asks about a batch used months ago. Each step that goes undocumented creates gaps a quality inspector won't ignore.
Staff need training to spot issues before they snowball. Knowing the signs of degradation—color change, unusual clumping, off odors—keeps mistakes from reaching the production line. Regular refresher courses help catch simple errors. If a mistake does slip through, a clear protocol for quarantine and disposal limits risk to patients and keeps compliance in check.
Storing and handling Poloxamer 407 takes more than a checklist. It’s about consistent care in every step, from how the product is received to how it goes out for compounding. Little details like airtight storage and dedicated utensils go a long way. In a sector where every detail counts, putting in the effort up front saves endless trouble later on.
People ask a lot about Poloxamer 407, especially with all the technical standards like BP, EP, USP floating around. To some, it looks like one more chemical in a crowded shelf, but it works hard behind the scenes. I’ve seen in the lab how a well-chosen excipient can turn a struggling tablet into a success, and Poloxamer 407 often plays that starring role as a surfactant and solubilizer. The big question folks bring up: does this stuff gel well—literally and figuratively—with the other ingredients drug makers use week in, week out?
From experience, mixing ingredients isn’t just science; it’s a hands-on, sometimes unpredictable art. Poloxamer 407 stands out by blending seamlessly with both hydrophilic and lipophilic drugs. If you’re dealing with a tough-to-dissolve molecule, this is the stuff you reach for. It grabs hold of oily actives and brings them into a water-based solution. If you’re working on an oral liquid or a topical gel, you see Poloxamer 407 handling things drugs like carbamazepine or diclofenac can throw at it.
Research backs up what we see on the bench. Poloxamer 407 partners up with commonly used cellulose derivatives (like HPMC or methylcellulose) without causing gelling problems or precipitation. That might sound dry, but in practice, it keeps products smooth, clear, and stable, even after months on the shelf.
People run into real trouble once ionic salts enter the picture. Electrolytes like sodium chloride or calcium chloride can mess with the gel structure, speeding up or delaying gelation. Every formulator has heard stories about beautiful gels breaking down right in the stability chamber due to these interactions. From my time on development teams, I know adjusting salt levels or blend temperatures keeps things on track.
Oil-based ingredients—triglycerides, some vitamins, and oily flavorings—usually blend well, but tossing in too much can break the gel structure. Running pre-formulation tests with real active pharmaceutical ingredients (APIs), not just model compounds, shines a spotlight on these incompatibilities long before production starts.
I’ve seen teams turn challenges into solutions by using buffer systems, changing the order of mixing, or introducing stabilizers like EDTA when cation-heavy drugs threaten stability. Sometimes adding a little more or less Poloxamer 407 flips failure to success. The real experts read incompatibility not as a stop sign, but as a cue to tweak, trial, and test different blends.
Looking at regulatory standards, BP, EP, and USP bring reassurance. Poloxamer 407 made to these standards stays consistent across batches, meaning fewer unwelcome surprises. That matters a lot when you consider scaling up—patients count on every dose working exactly as promised.
I’ve worked alongside pharmacists who measure shelf life not in years, but in how many patients they’ve helped avoid hospital trips. A formulation that holds together through humidity, heat, and shipping means fewer recalls and a better reputation. Gels and liquids built with Poloxamer 407 get dispensed in clinics and pharmacies worldwide, underscoring how much compatibility matters in the end product.
Choosing Poloxamer 407 isn’t about following a trend—it’s about leaning on solid science, decades of real-world use, and paying attention to each ingredient’s presence in the system. At the end of the day, delivering medicines safely and reliably takes more than the right paperwork. It’s about making sure every ingredient, including Poloxamer 407 BP EP USP, plays well with the rest and always serves the needs of patients and healthcare workers alike.
| Identifiers | |
| UN number | Not regulated |
| Properties | |
| Odor | Odorless |
Chengguan District, Lanzhou, Gansu, China
